Crispr Gen Editing
Crispr Gen Editing

Filter

Locations


Result types


Type of company


Industries


Company status

Number of employees

to

Founding year

to


Lock keywords

Exclude keywords

Optional keywords

Clear filters

Products and services for "Crispr Gen Editing"

Image for Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 | YEDA Technology Transfer
Product

Verified

Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 | YEDA Technology Transfer

OverviewCRISPR-Cas9 is a powerful tool for genome editing, widely used for basic research and the development of treatments for genetic diseases. However, its efficiency is currently limited. The current technology is a new chimeric Cas9 fused to a domain that recruits DNA repair factors directly to the genomic site that is being edited, thus doubling the efficiency of ‘error-free’ genome editing. This novel and highly efficient chimeric version of the Cas9 endonuclease is thus particularly relevant for clinical gene therapy applications. , Background and Unmet NeedCRISPR-Cas9 is a powerful tool for genome editing that allows researchers to modify genomes easily, accurately, and efficiently. It is widely used in various applications in basic as well as translational research and holds great promise in the development of new treatments for genetic diseases. For these reasons, CRISPR-Cas9 has entitled its co-developers the Nobel Prize in Chemistry for 2020. CRISPR-Cas9 utilizes Cas9, which makes a double-strand break in the genome in a specific location directed by a guide RNA. Once the cut is made, new DNA sequences can be introduced by employing the intrinsic DNA repair machinery, homology-directed repair (HDR). However, the DNA breaks can also be repaired without adding the desired DNA sequences by an alternative, more predominant cellular mechanism, called non-homologous end-joining (NHEJ). Therefore, achieving the desired result can often be inefficient. Previous approaches to this problem have used knockdown or pharmacological inhibition of NHEJ components, or cell cycle manipulation, in order to shift the balance towards HDR. However, altering the global DNA repair mechanism in the cell may result in undesired random mutations. , The SolutionYosef Shaul and his team developed a chimeric Cas9, which targets HDR factors directly to the DNA break site, resulting in a two-fold more efficient genome editing. , Technology Essence To increase the efficiency of CRISPR-Cas9 genome editing, HDR factors are targeted directly to the break site. This is achieved by a newly designed chimeric construct of Cas9, where the Cas9 nuclease is fused to a viral domain taken from Herpes Simplex Virus (HSV-1). This domain is a short, intrinsically disordered sequence that specifically recruits cellular factors that facilitate HDR. The chimeric Cas9 construct was two-fold more efficient in promoting specific editing of genomic loci and highly efficient in correcting a genomic point mutation. These chimeric Cas9 constructs provide a simple and versatile means for improving CRISPR-mediated genome editing.1,2 , Applications and Advantages Useful for gene therapy applications and basic science research A simple method that only requires substitution of the Cas9 protein with the modified version, and no other special reagents or treatments are required Short fused recruitment domain which lacks intrinsic enzymatic activity The chimeric Cas9 is more efficient at very low concentration of the protein, predicted to have fewer off-target effects, therefore it is particularly relevant for clinical applications Promoting HDR machinery locally at the break site without perturbing global DNA repair pathways , Development Status The chimeric protein was designed, purified and successfully tested on several human, mouse, and hamster cell lines, as well as in a clinically-relevant setup, namely by targeted editing of the SCD causative mutation at the HBB locus in human CD34+ hematopoietic stem and progenitor cells. The editing was made using small insertions/point mutations and large insertions (e.g. fluorescent proteins/other cassettes encoded by plasmid donors).   , ReferencesBenitez EK, Lomova Kaufman A, Cervantes L, et al. Global and Local Manipulation of DNA Repair Mechanisms to Alter Site-Specific Gene Editing Outcomes in Hematopoietic Stem Cells. Front Genome Ed. 2020;2:60154 doi:10.3389/fgeed.2020.601541   Reuven N, Adler J, Broennimann K, Myers N, Shaul Y. Recruitment of DNA Repair MRN Complex by Intrinsically Disordered Protein Domain Fused to Cas9 Improves Efficiency of CRISPR-Mediated Genome Editing. Biomolecules. 2019;9(10):584. doi:10.3390/biom9100584

by Yeda Research and Development Co. Ltd

Image for CRISPR-Quest Gene Editing Test | DiaCarta, Inc.
Product

Verified

CRISPR-Quest Gene Editing Test | DiaCarta, Inc.

CRISPR-Quest Gene Editing Test | Screening Mutant Clones after CRISPR Gene Editing | How Does the XNA Screening Work? | We can synthesize the XNA enough for 100 and 500 reactions for your screening needs. The reactions come with the qPCR mix, one pair of qPCR primers, XNA, positive and negative controls. Larger batch of custom synthesis is also available. | CRISPR Makes it Easier for Creating Stable Cell Lines with Particular Gene Mutations | Challenges for Screening for Desired Mutants from CRISPR Gene Editing | PCR followed by restriction enzyme digestions | PCR followed by mismatch assays | High resolution melting analysis | Capillary electrophoresis | Sanger sequencing combined with PCR | Western blot | Competition-based PCR method | Utilizing XNA Technology for Mutant Screening | Fast Results | No Manual Design | Ultra-Sensitivity | CRISPR-Quest Gene Editing Test Supporting Data | CRISPR-Quest Gene Editing Test Product Specifications | Resources | Marketing Brochure - XNA Customized Service

by DiaCarta

Image for CRISPR/Cas9 Editing Technology | All about this solution | genOway
Product

Verified

CRISPR/Cas9 Editing Technology | All about this solution | genOway

CRISPR/Cas9 Gene Editing | CRISPR/Cas9 Structure | CRISPR/Cas9 Mechanisms of Action | CRISPR/Cas9 Efficacy | CRISPR/Cas9 Off-Target Activity | Genetic Background Used with CRISPR/Cas9 Nucleases | Constitutive Knockout Models: Mutation Types Created by CRISPR/Cas9 Nucleases | Knockin Models: Mutation Types Created by CRISPR/Cas9 Nucleases | genOway's Ongoing R&D Programs | a) Multi-Targeting Models Using CRISPR/Cas9 | b) Large Deletions Using CRISPR/Cas9 | c) CRISPR/Cas9 Off-Target Effects | References

by genOway

Image for CRISPR/Cas9 Editing Technology | All about this solution | genOway
Product

Verified

CRISPR/Cas9 Editing Technology | All about this solution | genOway

CRISPR/Cas9 Gene Editing | CRISPR/Cas9 Structure | CRISPR/Cas9 Mechanisms of Action | CRISPR/Cas9 Efficacy | CRISPR/Cas9 Off-Target Activity | Genetic Background Used with CRISPR/Cas9 Nucleases | Constitutive Knockout Models: Mutation Types Created by CRISPR/Cas9 Nucleases | Knockin Models: Mutation Types Created by CRISPR/Cas9 Nucleases | genOway's Ongoing R&D Programs | a) Multi-Targeting Models Using CRISPR/Cas9 | b) Large Deletions Using CRISPR/Cas9 | c) CRISPR/Cas9 Off-Target Effects | References

by genOway

Image for CRISPR | Technologies | Crown Bioscience
Product

Verified

CRISPR | Technologies | Crown Bioscience

The CRISPR/Cas9 system is a cutting-edge gene editing technology that allows for precise and efficient editing of a cell's DNA.

by Crown Bioscience

Image for CRISPR/Cas9, Gene Editing Tool | OriGene
Product

Verified

CRISPR/Cas9, Gene Editing Tool | OriGene

什么是CRISPR? | 产品与服务 | CRISPR资源 | References | 基因表达 | 相关产品

by Beijing Origene Biotechnology Co., Ltd.

31 companies for "Crispr Gen Editing"

Branca Bunus Ltd's Logo

Dublin, Ireland

1-10 Employees

2019

Our Mission“To pioneer innovation through dedication in developing polymer based gene therapy transformative medicines“. Branca Bunús Ltd is a UCD start-up gene therapy company founded by Prof Wenxin Wang. Branca Bunús Ltd is dedicated to developing and commercialising gene therapy products for the treatments of patients suffering from genetic disorders around the world. Our patented gene therapy platform technology centres on a non-viral polymer based delivery approach. Our initial focus is the development of a CRISPR gene editing therapy delivered using our unique non-viral polymer platform technology for the treatment of the rare skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). Branca Bunús Ltd is dedicated to developing and commercialising polymer based gene therapeutics for patients suffering from genetic disorders around the world. Branca Bunús Ltd is a UCD start-up gene therapy company founded by Prof.

+

Featured

Core business
Image for CRISPR Gene Editing:

CRISPR Gene Editing:

... CRISPR Gene Editing: ...

Beijing SBS Genetech Co.,Ltd.'s Logo

Beijing, China

11-50 Employees

2000

We provide optimized solutions for life science research. We are honored to create value for our customers and facilitate the development of science. Our high quality products are trusted by researchers and scientists in top universities and institutes. Our support personnel is all experts with an average of more than 10 years of working experience. Thousands of papers have been published in the world's top academic journals with our products.

+

Featured

Product
Image for SD DNA Polymerase (1,000U)

SD DNA Polymerase (1,000U)

... CRISPR Gene Editing ...

genOway's Logo

Lyon, France

51-100 Employees

1999

The current genOway management committee is composed of six members: Alexandre Fraichard, Benjamin Bruneau, Cyrielle Chabrier, Florent Pons, Yacine Cherifi and Kader Thiam. We are the only company to invest heavily in this consulting activity, and each project feasibility analysis represents seven days of full-time equivalent activity of experts in bioinformatics, gene targeting, molecular biology, and cell biology. At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. Founded in 1999 by a four-member team around founder Alexandre Fraichard, genOway now has risen to become a leader in the field of customized, genetically modified (GM) mouse, rat and cell model creation. We have built a unique license portfolio for all technologies used, including exclusive licenses, which we are allowed to sublicense. Furthermore, our customers retain ownership of the deliverables and can patent the model developed. This provides you with cohorts ready for experimentation.

+

Featured

Product
Image for CRISPR/Cas9 Gene Editing

CRISPR/Cas9 Gene Editing

... CRISPR/Cas9 Gene Editing ...

DiaCarta's Logo

Hayward, United States

11-50 Employees

2011

At DiaCarta, our mission is to improve the lives of cancer patients through innovative precision diagnostics. We are committed to providing accurate, reliable, and affordable diagnostics that help physicians make informed treatment decisions. Patient-Centric operations: Our mission is to provide innovative and affordable solutions for cancer patient management, and we prioritize the needs of patients and their families in everything we do. Innovation: We are committed to advancing precision diagnostics and improving patient outcomes through cutting-edge research and development. Continuous Improvement: We are dedicated to ongoing improvement and innovation, and we invest in the development of our team, our products, and our infrastructure to better serve our customers and achieve our mission. We are committed to designing and manufacturing products with the good of the patient in mind. DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage. DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience.

+

Featured

Product
Image for CRISPR-Quest Gene Editing Test

CRISPR-Quest Gene Editing Test

... CRISPR-Quest Gene Editing Test | DiaCarta, Inc. ...

Yeda Research and Development Co. Ltd's Logo

Rishon LeZion, Israel

11-50 Employees

1959

YEDA Technology Transfer from the Weizmann Institute of Science. Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. The innovation ecosystem comprises of three separate but interrelated units within the Institute.

+

Featured

Product
Image for Pharmaceuticals Research Tools Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930)

Pharmaceuticals Research Tools Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930)

... Pharmaceuticals Research Tools Higher Efficiency of CRISPR Gene Editing Using Chimeric Cas9 (No. T4-1930) ...

CRISPR Therapeutics's Logo

Cambridge, United States

101-250 Employees

2013

We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.

+

Featured

Core business
Image for CRISPR Therapeutics Announces European Patent for CRISPR/Cas… | CRISPR

CRISPR Therapeutics Announces European Patent for CRISPR/Cas… | CRISPR

... CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing ...

Beam Therapeutics's Logo

Cambridge, United States

51-100 Employees

2017

Our vision is to create life-long cures through gene-based editing – one letter at a time. We are located at: 238 Main Street, Cambridge, MA 02142. We are located at: 10 Davis Drive, Durham, North Carolina 27709. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases. Giuseppe Ciaramella is the President of Beam Therapeutics. Gopi Shanker is the Chief Scientific Officer of Beam Therapeutics. O’Connor holds a bachelor’s degree from Providence College. Brian Riley, an experienced leader in operations, quality and manufacturing, is Chief Manufacturing Officer at Beam.

+

Featured

Core business
Image for Our Story | Beam Therapeutics

Our Story | Beam Therapeutics

... Keith Joung, scientific pioneers in CRISPR gene editing. Bringing together their passion, expertise, and determination to develop lifelong cures for patients suffering from serious diseases. ...

Rocket Communications, Inc.'s Logo

San Francisco, United States

11-50 Employees

1998

Created in a first of its kind partnership with the US Space Force, Astro provides a complete UX Tool Kit for mission critical applications. Thermo Fisher Scientific is the world leader in scientific and medical devices. They help their customers accelerate life sciences research, solve complex analytical challenges, and increase productivity in their laboratories. CyDesign provides a physics-based modeling system that allows engineers to quickly assess design options against requirements during the conceptual design stage.

+

Featured

Product
Image for GENOME APP | Inscripta - Rocket Communications

GENOME APP | Inscripta - Rocket Communications

... Revolutionized and accelerated the CRISPR gene editing process with a ...

Crown Bioscience's Logo

United States

251-500 Employees

2006

Headquartered in California, US, Crown Bioscience is a global contract research organization (CRO) providing discovery, preclinical and translational platforms and services to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. We are known for our high-quality and expansive in vivo, in vitro, and ex vivo preclinical models, and partner with our clients to quantify the efficacy and pharmacological profile of their drug candidate(s) before they move into the clinic. We aim to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Crown Bioscience is a division of JSR Life Sciences, part of the multinational JSR Corporation. JSR Life Sciences provides specialized technology, products, materials, and services to biopharmaceutical companies and life science researchers.

+

Featured

Product
Image for CRISPR/Cas9 gene editing platform

CRISPR/Cas9 gene editing platform

... Revolutionize Your Research with our CRISPR/Cas9 Gene Editing ...

Hunterian Medicine's Logo

Cambridge, United States

1-10 Employees

2016

The Hunterian technology uses a novel genetic element to enable in vivo delivery via a single adeno-associated virus (AAV). Hunterian Medicine is a gene editing company poised to unleash the full potential of CRISPR. Hunterian Medicine’s technology opens an immediate path to develop cures for a vast number of genetic diseases where no FDA approved therapies exist. Hunterian Medicine’s technology uses a novel “2-for-1” genetic control element, a bidirectional promoter, to overcome the challenge of delivering CRISPR via AAV. Hunterian's approach has the immediate potential to bring multiple CRISPR technologies to the clinic and dramatically accelerate the development of CRISPR-based therapeutics. CRISPR is a revolutionary gene-editing tool with the ability to edit nearly any DNA sequence within the human genome, and the potential to correct a multitude of disease-causing mutations. Our patented platform technology solves the CRISPR delivery problem by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). By freeing up critical space in AAV, Hunterian Medicine’s technology allows for the development of the safest and most effective CRISPR-based therapeutics.

+

Featured

Product
Image for The Technology — Hunterian Medicine

The Technology — Hunterian Medicine

... MIT Technology Review has called CRISPR-mediated gene editing “the biggest biotech discovery of the century.” ...

Show More

„Crispr Gen Editing“

CRISPR-Cas Genome Editing is a technology that enables scientists to make precise changes to an organism’s DNA. It works by using an enzyme to cut the DNA at a specific location, allowing researchers to remove, add, or alter genetic material. The efficiency and accuracy of this technique has revolutionized the fields of genetic engineering and biomedical research. With CRISPR-Cas Genome Editing, scientists are now able to make precise changes to an organism’s genome with unprecedented accuracy and efficiency, paving the way for novel treatments and cures for diseases.